Zobrazeno 1 - 10
of 46
pro vyhledávání: '"James G. Jakowatz"'
Autor:
Frank L. Meyskens, Alistair J. Cochran, Sung-Jig Lim, Joseph A. Tangrea, Craig A. Elmets, Wen-Pin Chen, Philip M. Carpenter, Ronald J. Barr, Christine E. McLaren, Jaye L. Viner, James G. Jakowatz, Jonathan S. Zager, Sancy A. Leachman, Kenneth G. Linden
On the basis of large cardiovascular clinical trials of lipid-lowering agents that showed a considerable decrease in the incidence of primary melanomas in the active agent arm, we have carried out a randomized, double-blind clinical trial examining t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e177b4ac200b4c5a5737854ad15ee51
https://doi.org/10.1158/1940-6207.c.6544800
https://doi.org/10.1158/1940-6207.c.6544800
Autor:
Frank L. Meyskens, Alistair J. Cochran, Sung-Jig Lim, Joseph A. Tangrea, Craig A. Elmets, Wen-Pin Chen, Philip M. Carpenter, Ronald J. Barr, Christine E. McLaren, Jaye L. Viner, James G. Jakowatz, Jonathan S. Zager, Sancy A. Leachman, Kenneth G. Linden
PDF file - 3911KB, Supplementary Figure S1. Examples of classifications of nevomelanocytic neoplasms histopathologically evaluated for the primary endpoint of the study. Supplementary Figure S2. Examples of a target atypical nevus photographed pre an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c8ac587f39326d937fd2e37a5cf1e0
https://doi.org/10.1158/1940-6207.22525557
https://doi.org/10.1158/1940-6207.22525557
Autor:
Frank L. Meyskens, Alistair J. Cochran, Sung-Jig Lim, Joseph A. Tangrea, Craig A. Elmets, Wen-Pin Chen, Philip M. Carpenter, Ronald J. Barr, Christine E. McLaren, Jaye L. Viner, James G. Jakowatz, Jonathan S. Zager, Sancy A. Leachman, Kenneth G. Linden
PDF file - 53KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01391551d8e0b0e5dd14cd38bc292561
https://doi.org/10.1158/1940-6207.22525560
https://doi.org/10.1158/1940-6207.22525560
Autor:
Frank L. Meyskens, Alistair J. Cochran, Sung-Jig Lim, Joseph A. Tangrea, Craig A. Elmets, Wen-Pin Chen, Philip M. Carpenter, Ronald J. Barr, Christine E. McLaren, Jaye L. Viner, James G. Jakowatz, Jonathan S. Zager, Sancy A. Leachman, Kenneth G. Linden
PDF file - 111KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::436df26f46937a13f76d6e194254653a
https://doi.org/10.1158/1940-6207.22525554.v1
https://doi.org/10.1158/1940-6207.22525554.v1
Autor:
Frank L. Meyskens, Alistair J. Cochran, Sung-Jig Lim, Joseph A. Tangrea, Craig A. Elmets, Wen-Pin Chen, Philip M. Carpenter, Ronald J. Barr, Christine E. McLaren, Jaye L. Viner, James G. Jakowatz, Jonathan S. Zager, Sancy A. Leachman, Kenneth G. Linden
PDF file - 64KB, Supplementary Table S1. Descriptive statistics for concordance evaluation of positive control slides. Supplementary Table S2. Evaluation of laboratory data.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::915403af3c0b2f5cfc5549079e05bef5
https://doi.org/10.1158/1940-6207.22525551.v1
https://doi.org/10.1158/1940-6207.22525551.v1
Autor:
Maki Yamamoto, Seung Ah Lee, Gregory R. D. Evans, Allison C. Hu, James G. Jakowatz, Emily G. Clark
Publikováno v:
Plastic and Reconstructive Surgery Global Open
Background The role of surgical reconstruction following melanoma extirpation is well recognized. Although technical considerations depend on patient anatomy and surgeon preference, the optimal timing of reconstruction remains unclear. This study aim
Publikováno v:
Journal of Clinical Oncology. 38:e22062-e22062
e22062 Background: This open-label, phase II study investigated the clinical activity and safety profile of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR) in patients with stage II
Autor:
Katherine Osann, John P. Fruehauf, Monica El-Masry, Basmina Parmakhtiar, Maki Yamamoto, James G. Jakowatz
Publikováno v:
Cancer Chemotherapy and Pharmacology
Fruehauf, JP; El-Masry, M; Osann, K; Parmakhtiar, B; Yamamoto, M; & Jakowatz, JG. (2018). Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 82(2), 353-360. doi: 10.1007/s00280-018-3624-6. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5xn2f71m
Fruehauf, JP; El-Masry, M; Osann, K; Parmakhtiar, B; Yamamoto, M; & Jakowatz, JG. (2018). Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 82(2), 353-360. doi: 10.1007/s00280-018-3624-6. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/5xn2f71m
Purpose This phase II study evaluated the safety and clinical activity of pazopanib, a potent and mutlitargeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs)-1, -2 and -3, platelet-derived growth factor rece
Autor:
Zhi-Ming Huang, Ruby Ghadially, Lili Yue, Stanley P. L. Leong, Alex Charruyer-Reinwald, Maria L. Wei, James G. Jakowatz, Stephen Fong
Publikováno v:
Melanoma Research. 25:138-148
Cells with aldehyde dehydrogenase activity (ALDH+) are the most tumorigenic cells in many cancers, including melanoma, making ALDH a candidate therapeutic target. We examined the effects of chemical inhibition of ALDH1 on the response of human melano
Autor:
Jonathan S. Zager, Ronald J. Barr, Christine E. McLaren, Jaye L. Viner, Wen-Pin Chen, Frank L. Meyskens, Craig A. Elmets, Sung Jig Lim, Philip M. Carpenter, Kenneth G. Linden, James G. Jakowatz, Alistair J. Cochran, Sancy A. Leachman, Joseph A. Tangrea
Publikováno v:
Cancer Prevention Research. 7:496-504
On the basis of large cardiovascular clinical trials of lipid-lowering agents that showed a considerable decrease in the incidence of primary melanomas in the active agent arm, we have carried out a randomized, double-blind clinical trial examining t